These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. [Experience with Selexipag to Treat Pulmonary Arterial Hypertension]. Karelkina EV; Goncharova NS; Simakova MA; Moiseeva OM Kardiologiia; 2020 Mar; 60(4):36-42. PubMed ID: 32394855 [TBL] [Abstract][Full Text] [Related]
33. Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies. Ghosh RK; Ball S; Das A; Bandyopadhyay D; Mondal S; Saha D; Gupta A J Clin Pharmacol; 2017 May; 57(5):547-557. PubMed ID: 27670133 [TBL] [Abstract][Full Text] [Related]
34. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. Beghetti M; Channick RN; Chin KM; Di Scala L; Gaine S; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Galiè N Eur J Heart Fail; 2019 Mar; 21(3):352-359. PubMed ID: 30632656 [TBL] [Abstract][Full Text] [Related]
35. Selexipag: First Global Approval. Scott LJ Drugs; 2016 Mar; 76(3):413-8. PubMed ID: 26846322 [TBL] [Abstract][Full Text] [Related]
36. An evaluation of selexipag for the treatment of pulmonary hypertension. Panagiotidou E; Boutou A; Pitsiou G Expert Opin Pharmacother; 2021 Jan; 22(1):29-36. PubMed ID: 32867545 [TBL] [Abstract][Full Text] [Related]
37. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag. Verlinden NJ; Walter C; Raina A; Benza RL J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036 [TBL] [Abstract][Full Text] [Related]
38. [Pharmacological characteristics and clinical study results of Selexipag (Uptravi Kuwano K; Kosugi K; Fuchikami C; Funaki S Nihon Yakurigaku Zasshi; 2021; 156(3):178-186. PubMed ID: 33952848 [TBL] [Abstract][Full Text] [Related]
39. Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy. Adachi S; Nishiyama I; Yasuda K; Yoshida M; Nakano Y; Kondo T; Murohara T J Cardiol Cases; 2022 Jul; 26(1):42-45. PubMed ID: 35923524 [TBL] [Abstract][Full Text] [Related]
40. Baseline history of patients using selexipag for pulmonary arterial hypertension. Highland KB; Hull M; Pruett J; Elliott C; Tsang Y; Drake W Ther Adv Respir Dis; 2019; 13():1753466619843774. PubMed ID: 30983530 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]